Response and safety profile of neoadjuvant nivolumab for resectable lung cancer
25 Apr 2018
Response and safety profile of neoadjuvant nivolumab for resectable lung cancer
Doubled survival in metastatic lung cancer with combination therapy
Combined immuno-chemotherapy improves survival and responses in metastatic lung cancer
Results from CheckMate-227 : Immune combination reaches PFS endpoint
How the SBIR development centre funds cancer initiatives
Supporting technological initiatives in low and middle income countries
ecancer e-learning
One off PSA prostate screening for men does not save lives
The Integrative Cancer Epidemiology Programme
Editor’s Choice for March 2018
Coping with extreme fatigue after cancer
Management of marker negative stage II testicular cancer